1. Scrip
  2. >>R&D

Could Tecentriq's Bladder Cancer Setback Be A Class Effect?

 
• By Sukaina Virji

The failure earlier this week of Roche's Tecentriq in second line bladder cancer left both the company and analysts surprised. Bladder cancer is a competitive space with a number of other immune-oncology products at or close to market. What does the Tecentriq result mean for them?

Inchworms
Does Roche's failure indicate need for route change for IO in bladder cancer? • Source: Shutterstock

Roche's difficulties in confirming Tecentriq's efficacy in second line bladder cancer will likely have sent a shiver of unease through its competitors, rather than a cheer. (Also see "Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial" - Scrip, 10 May, 2017.)

Tecentriq (atezolizumab) is one of five similar products on or close to market for the same indication. Could this be...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Ionis’s Olezarsen Data Meet Multiple Marks In Blockbuster sHTG Indication

 
• By Mandy Jackson

Phase III CORE and CORE2 results presented at the AHA meeting in severe hypertriglyceridemia showed durable triglyceride lowering and reductions in acute pancreatitis across patient subgroups, supporting expansion of Tryngolza (olezarsen) into a second, larger indication.

Amgen’s ‘Stunning’ VESALIUS Results Could Push Repatha Into The Mainstream

 
• By Mandy Jackson

Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Centessa’s Sleep Disorder Drug Shows Broad Potential But Faces Tough Competition

 
• By Sushmita Panda

Pivotal data next year will be key for the early-stage biotech as analysts remain divided on ORX750's potential.

More from Scrip

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid

 
• By Kevin Grogan

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

Centessa’s Sleep Disorder Drug Shows Broad Potential But Faces Tough Competition

 
• By Sushmita Panda

Pivotal data next year will be key for the early-stage biotech as analysts remain divided on ORX750's potential.